Researchers Launch New Breast Cancer Blood Test Trial
A new clinical trial in Los Angeles is testing if a liquid biopsy can identify breast cancer at an early stage.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you believe new blood-based screening tests will improve early detection for breast cancer?
Researchers at the USC Norris Comprehensive Cancer Center have launched a clinical trial to evaluate a new liquid biopsy for early-stage breast cancer detection. The blood-based test aims to identify markers that could help detect the disease at Stage I, though it is not a replacement for standard screenings like mammograms.
Why it matters
Detecting breast cancer at Stage I can significantly improve treatment options and outcomes for patients. This study aims to determine if blood samples can successfully identify the disease early in its progression, addressing a critical need among the 300,000 Americans diagnosed with breast cancer annually.
This Phase 1 clinical trial involves collecting blood samples from participants one year apart to evaluate the detection capabilities of a new liquid biopsy. While preliminary, researchers are testing the assay's ability to identify early-stage breast cancer before finalizing potential phase 2 plans.
The players
USC Norris Comprehensive Cancer Center
A research institution conducting clinical trials and providing cancer care in Los Angeles.
USC Michelson Center Convergent Science Institute in Cancer
An academic research center focused on developing new technologies for cancer detection and treatment.
The details
The liquid biopsy, developed at the USC Michelson Center Convergent Science Institute in Cancer, works by identifying rare cancer-associated cells and tumor-associated large extracellular vesicles in the blood. Researchers are testing whether these specific biological signals can reliably detect cancer as early as Stage I. It is important to note that this experimental test is not a substitute for standard diagnostic tools like mammograms or breast biopsies.
Timeline
Participants will have two blood samples collected one year apart.
Health Landscape
The development of liquid biopsies represents an evolving frontier in oncology, aiming to supplement traditional imaging with molecular insights. This trial explores how blood-based detection fits into the broader arc of early intervention strategies.
While this experimental test is currently limited to a clinical trial, it highlights the importance of staying current with established screenings like mammograms. If you have questions about cancer screening options or your personal risk factors, consult your primary care physician.
The takeaway
Early detection remains the most effective strategy for managing breast cancer outcomes. Always maintain your routine screening schedule and discuss any concerns about emerging diagnostic technologies with your physician.
Further reading
For more on current detection methods, visit Cancer.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe new blood-based screening tests will improve early detection for breast cancer?
